HOME > About the KDDF > Introduce

Introduction of KDDF

Established in September 2011, Korea Drug Development Fund (KDDF) is a government-initiated drug development program. It aims to transform Korea into the global leader for new drug development. It has a budget of 1 billion US dollars to enhance national competitiveness in the global arena. KDDF is now backed by three health-related Korean ministries: the Ministry of Science, ICT, and Future Planning, the Ministry of Trade, Industry, and Energy, and the Ministry of Health and Welfare. KDDF aims to enhance development of at least 10 new global blockbuster drugs by the year 2020.
Innovation Oriented Global Drug Development Program
“Novel & Innovative Pipeline supporting business”
  • As a part of open innovative strategy, the global pharmaceuticals' demand for technology transfer involved with novel and innovative and new drug substances such as the first-in-class antibodies, peptides, synthetic products, RNA interference (RNAi) nanoparticles, gene therapies, therapeutic vaccines and natural products is now very high. This trend is considered to be continued and enhanced even further.
  • Global pharmaceutical companies clearly show a great deal of interest on innovative pipeline at its late phase (Phase II completed) and the deal dollar value is astronomical. Therefore intensive support for pipelines at least after its pre-clinical trials (Pre-clinical to Phase II) is required.
  • Considering the reality of domestic pharmaceuticals with relatively low competency in terms of clinical development and crisis management capability, the project selection criteria mainly focus on novelty and mechanism suitability of drug substance.
  • High Risk, High Return : Most of competitors including global big pharmaceuticals focus on therapeutic areas with high medical unmet needs. However, KDDF also focus on novel target-novel material pipelines as well.
  • The amount of money and the period required are defined case by case (study features, the situation of research institute). Therefore, the evaluation is made on absolute scale base, not relative scale.
Goal(Market)-Driven Global Drug Development Program
“Big Pharmaceutical-Joint R&D Program”
  • The big pharmaceuticals represent global or multinational pharmaceuticals which have capacity (capital or international sales network) to purchase promising pipelines currently under domestic research and development.
  • The Joint R&D Program is a business to select, invest in and manage the study task in partnership between those global pharmaceuticals and KDDF, in which possibility of licensing-out becomes to be high as the end user of global technology transfer directly gets involved with initial development phases. In addition, there comes advantage of having opportunity to learn advanced development techniques from global pharmaceuticals during the process of business.
  • Since KDDF planned and managed investment structure, operation mode, negotiation subject and process procedures of the Joint R & D in 2015, it is now operating the Joint R & D Program with the world no. 1 healthcare company, Johnson & Johnson Innovation. Furthermore, the Joint R & D Programs with other global pharmaceuticals are under active discussion.
R&D Development Support Program

1) Drug Evaluation Program

2) Global Licencing Support Project
3) Procedures for Global Licensing Support Program
4) KDDF Database Program to provide knowledge and Information for New Drug Development
5) Global C&D Support Program
  • The Drug Evaluation Program is to evaluate the value of pipelines supported by KDDF. After making agreement with research institute, KDDF hires external consultants to figure out the estimate value of the project.
  • The evaluation mainly covers aspects such as technological competitiveness, intellectual property right and marketability, and it aims to enhance portfolio investment efficacy and set up strategic direction by producing objective quantitative performance indicator.
  • The Global Licensing Support Project is to follow-up the Drug Evaluation Program mentioned above, which is conducted by the specialized external institution after consultation with the research institute.
  • The project aims to develop sales material kit based on technology-marketing data, advantages and disadvantages of the target drug and drug approval information. The company can have their own value-up storyline and differentiated licensing competency.
  • It is necessary for domestic new drug researchers to have an access to information of global new drug development trend in forms of reliable database. KDDF offers such data packages that contain market information or strategic insights.
  • The KDDF DB program aims to contribute to globalization of domestic new drug development by sharing database of knowledge/information and management techniques acquired by KDDF over last 4 years.
  • The Global C&D Program is to introduce promising pipelines currently being studied outside Korea to domestic research institutes, in forms of licensing-in or co-development.
  • The program is based on widely accepted drug development trend, the open innovation. At the same time, obtaining more pipelines is essential to achieve the main goal of KDDF, to develop at least 10 global drugs before year 2020.
  • KDDF host the Tech-Fair, where sourcing and screening of promising foreign substances are done and sellers and buyers meet to discuss business affairs. After the Fair, consultation on various issues raised from the process of negotiation is provided for successful pipeline trade.
6) Program Process Procedures